Enzymic conversion of aflatoxin B1 to a derivative inhibiting in vitro transcription  by Moulé, Y. & Frayssinet, C.
I’I:BS LETTERS September 1972 
ENZYMIC CONVERSION OF AFLATOXIN B, TO A DERIVATIVE 
INHIBITING IN VITRO TRANSCRIPTION 
Y. MOUL&nd C. FKAYSSINET 
lrlsritlri (/L’ Rc~chc~rclres S~ic~~r~~fiq~res SIIY k Cirrrcer, 94. I ‘illcjuif. l~rat~cc 
Rcceivcd 16 June 1972 
I. introduction 
Aflatoxin Bt, a verypotent hepatocarcinogen syn- 
thesized by Aspc@llus jLnws, strongly inhibits irz viva 
incorporation ol‘labelled prec~~rsors into KNA of rat 
liver (see the review by Wogan [ I 1 ) by itnpairing the 
transcriptional mechanisttt of the cell [Z-4] How- 
ever, the pure toxin fails to modify significantly the 
activity of an ill vifro system cornposed of a DNA 
teniplate and a KN.4 polymerase purified frotn bacte- 
ria 14. 5 1 or mammalian tissues IO] : hy contrast, 
crude a&toxin extracts prepared from Aspcrgihs 
flaws cultut-es at-e effective in inhibiting the RNA syn- 
thesizing system 141. These results suggest that 
atlatoxitt Bt must he converted to a reactive tnolccule 
prior to interfering with cell tnetaholisni. A sitnilar se- 
quence of events leas been clearly detnonstrated for 
other carcinogens (see the reviews by Farber [7] and 
Miller [8] ). 
This paper is related to the ettLymic activation of 
aflatoxin Bt: using microsumal preparations of rat 
liver. WC have obtained an allatoxin-derived ntetabolite 
which is capable 01‘ inhibiting transcription irl vifro. 
The tnechanistn of the inhibition has been studied. It 
has been shown that the active contpound acts on 
RNA polytnerase enzyme activity rather than on DNA 
tentplate ability. Moreover, initiation appcat-s to be 
the step of tt-attscription affected by the active cant- 
pound. The problem of the relationship between the 
carcinogenic potency of aflatoxin Bt and the inhibitory 
effect of its derivative on irl t+fro transcription will be 
discussed. 
2. hlaterials and methods 
Mole Wistar rats (Cotntnentry strain) weighing 
about 750 g received an intraperitoneal injection ot 
3-tttethylcllolantlircne (20 mg per kg) dissolved in 
olive oil. for two consecutive days before killing. The 
livers were quickly removed and chilled at 0”; they 
were homogenized in 10 vol of ice-cold 0.75 M su- 
crose in a Perspex homogenizer. The Itotttogenatc was 
filtered through three layers of surgical gauze; the tnicr 
sontal fraction was isolated according to Schneider 191 
Microsotnes were resuspended in 0.05 M phosphate 
buffer pH 7.4 (microsonles from I g of liver per tnl). 
The enr.ytnic conversion of atlatoxin B, was carried 
out at 37” in Erlenntcyet- tlasks. Each flask containc’d 
lOO/.q atlatoxin B, dissolved in 0.2 tttl acetone. 5 nll 
ot‘O.05 hl phosphate buffer pH 7.4. 2.75 ptnoles 
NADPH and I ml of niict-osonlal suspension. The tlask! 
were vigorously shaken for 30 min. The mixture was 
extracted three titnes with chloroform; the combined 
chloroform-soluble fractions were treated with Na2SQt 
and evaporated to dryness. The residue was dissolved 
in either propylene glycol or l-t-is-buffer. 
Thin-layer chromatography was performed on silica 
gel G-HR (Maclterey Nagel) coated plates using chloro- 
lornt:acctone (9: I ) for developtncnt. 
The KNA polynicrase system contained in 0.15 tttl: 
IO ptttoles Tris-buffer pH 0, 0.25 pntoles MnClzl I .2S 
I.ltttolcs MgC’I, . 3 ~tiiolcs P-met-captoetltati~)l, 80 pg 
calf thytttus DNA (unless otherwise stated). 0.025 
pntoles each of three unlabellcd nucleoside-5’-tryphos- 
phates (ATP. GTP CTP), 0.025 pn~oles of [2-t4C]UTP 
corresponding to 0.09 FCi, I:: coli KNA polymerase. 
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Number of preparations and quantity ot 
“compound X” added to the assay 
Sequential addition of components x2 x4a X7A1 X7Cl Atlatoxin UT 
to transcription assak 0.5 pg 0.4 /lg 0.75 /J&l 0.6 IJ:! 10 UF 
DNA + NTP (2 min at 37”) + enzyme, 
10 min at 37” (100) (100) (100) (100) (100) 
Part a DNA + compound X + NTP (2 min at 37 ) 
+ enzyme, 10 min at 37” 50 58 43 70 - 100 
Enzyme + DNA (2 min at 37 ‘)+ NTP. 
10 min at 37” (100) (100) 
Enzyme + NTP + compound X (2 min at 
Part b 37”) + DNA, 10 min at 37” 44 25 
Enzyme + DNA (2 min at 37”) 
+ compound X + NTP, 10 min at 37” 66 49 
DNA + NTP (2 min at 37”) + enzyme, 
Part c 2 min at 37” + compound X, 
8 min at 37” - 100 80 
Table 1 
~ffwt of &at&in H, derived metabolite (compound X) on the activity of an RNA synthesi& _ 11 wqtem using bacterial polymcrase. 
- 
The composition of the assay was described in Materials and methods. Atlatoxin B, and compound X, were dissolved in propylen 
glycol (0.05 ml); compounds X4,, X7AI and X7C1 were in solution in 0.01 hl Tris-II<‘1 buffer pll 7.8. The amounts of RNA 
polymerase enzyme used corresponded to 5.8 units (25 pg protein). * Compound X was replaced by 10 pg aflatosin 13, 
Compound X 2 
II I I 
0.05 0.25 0.5 1 1.5 2 
vg Compound X per assay 
>_ 
5_ 
0.42 clg X 4a 
.____---____. 
. .0.5pgx2 
._._.--f-. -.-. 1.5 ug X4b 
1 I 
20 a0 60 a0 100 120 
ii DNA per assay 
l‘ig. 1. Inhibition of RNA polymerase activity in the presence 
of progressively higher amounts of compound X. The RNA 
polymerase assay is described in Materials and methods. The 
amount of RNA polymerase used corresponded to 5.8 units 
(25 pg protein). Compound X2 was dissolved in 0.05 ml of 
propylene glycol. 
Fig. 2. t<ffect of progressively higher amounts of DNA on the 
inhibition of in r*itro transcription by compound X. Com- 
pound X2 was dissolved in 0.05 ml of propylene glycol; 
compounds X4a and X4b were in 0.0 I hl Tris-IICl buffer 
ptl 7.8. The amount of RNA polymerase corresponds to 5.8 
units (25 wg protein). 
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Aflatoxin B, or the aflatoxin-derived compound dis- 
solved in propylene glycol or Tris-buffer pH 7.5 was 
added in the amounts indicated in the figures. Con- 
trols contained the same volume of propylene glycol 
or Tris-buffer. The reaction was run in duplicate for 
10 min at 37”. Determination of incorporated radio- 
activity was performed as described previously [ IO] 
Purified RNA polymerase from E. coli was pur- 
chased from Miles Laboratories (Elkart, Indiana. 
USA) and atlatoxin B, from Makor (Jerusalem, Israel). 
3. Results 
Chloroform-soluble compounds. obtained by in- 
cubating atlatoxin BI in the presence of microsomes, 
were subjected to thin-layer chromatography on silica 
gel coated plates. A new blue fluorescent spot appear- 
ed with an RI. lower than that of aflatoxin B,. This 
new component was called “compound X”. 
The new fluorescent fraction was isolated by chro- 
matography of chloroform-soluble compounds through 
a silica column followed by elution with chloroform: 
ethanol (98.75 : 1.25). Compound X was estimated by 
fluorodensitometric measurement using the specific 
coefficient of aflatoxin B,. The absolute amounts of 
compound X reported in this paper should be cor- 
rected when its identification will have been done, al- 
lowing the determination of its own emission coeffi- 
cient. This problem is under investigation, 
loo_ 
Z 
0.42ugX4a 
I 
f--____. 
I 1 6 I I 
2.9 5.8 11.6 17.4 23.2 
Enzyme units per assay 
1:ig. 3. Effect of progressively higher amounts of E. coli RNA 
polymerase on the inhibition of in vitro transcription by com- 
pound X. Compounds X were in solution in Tris-HCI buffer 
0.01 M pH 7.8; each assay contained 80 ~.rg calf thymus DNA. 
v I 
a 6 
Time ‘Pmlnutes ) 
15 20 
1;i.g. 4. Time course incorporatron of I 14C\ UTI’ m an RNA 
poiymerase system in the presence of compound X added 
after initiation of the reaction. Compound X6 (2.6 pg) was 
dissolved in acetone (0.02 ml). At the time indicated by the 
arrow, control assays received 0.02 ml of acetone and the 
other series received 2.6 pg of compound X6 in solution in 
0.02 ml acetone; the assays were run for a further incubation 
and stopped as indicated in the figure. Addition of 0.02 ml 
acetone in the controls induced an 18% inhibition of the 
activity of assays performed without acetone. 
Compound X markedly inhibits the irl vitro RNA- 
synthesizing system, whereas aflatoxin B, is completeI! 
inactive (table 1, parts a and b). Although we observed 
some differences in the activity of the successive pre- 
parations of the aflatoxin-derived fraction (see Discus- 
sion) in most cases a 50% inhibition as compared to 
the control value was obtained for 0.5 to 0.8 pg ot 
compound X. a significant inhibition was observed for 
a dose as low as 0.05 pg for the most active preparation 
(fig. 1). However, whatever the batch of compound X 
the extent of inhibition always depends on the amount 
of compound X added. 
Further experiments were performed in order to 
provide information regarding the site of action of the 
aflatoxin-derived metabolite. Results reported in fig. 2 
show that the extent of inhibition of transcription is 
unaffected by increasing amounts of DNA template 
added in the assay regardless of whether DNA is a 
limiting or a non-limiting factor for the reaction. By 
contrast, addition of higher levels of RNA polymerase 
(2.9 to 23.2 units) relieves progressively the inhibitory 
effects on RNA synthesis (fig. 3). These facts suggest 
that compound X impairs iu vitro transcription by 
alteration of the RNA polymerase enzyme itself. 
54 
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Regarding the step of the transcriptional process 
affected, the results indicate that inhibition concerns 
primarily initiation since addition of compound X 3 
min after the reaction had started does not block the 
further elongation of chains initiated before action of 
the drug (table I, part c). The time course of the in- 
corporation of labelled UTP into polynucleotides 
(fig. 4) is similar to that observed for rifampicin and 
rifampicin AF/O. 13. two drugs which are known to 
inhibit specifically the initiation of chains, respectively, 
in bacterial [ 1 I] and mammalian systems [ I?]. This 
conclusion is strengthened by the fact that compound 
X fails to inhibit transcription carried out on isolated 
liver nuclei. Under these conditions it is known that no 
initiation of new chains takes place irz vitro: RNA poly- 
merase activity corresponds only to elongation of 
chains preinitiated. 
4. Discussion 
The enzymes involved in the metabolic detoxifica- 
tion by liver are tightly associated with microsomal 
membranes and are induced in response to administra- 
tion of hormones, drugs and carcinogens (see Brodie et 
al. [ 131 and Talalay [ 141 ). Enhanced enzymic capacity 
of microsomes obtained from rats treated with methyl- 
cholanthrene [IS] was used to achieve it? vitro conver- 
sion of ailatoxin B, By this technique, a fraction con- 
taining a new fluorescent component (compound X) 
derived from the toxin was obtained. Unlike aflatoxin 
B1, it inhibits in vitro activity of E. co/i polymerase. 
Further experiments will determine the action of this 
fraction on mammalian purified RNA polymerase. 
Depending on the preparations, the inhibitory ca- 
pacity of compound X shows some differences. How- 
ever, despite the quantitative variations, successive 
batches of compoun X have a reproducible action on 
the molecular mechanism of the transcription process 
(table I ; figs. 2 and 3). The foregoing results suggest 
that the compound X have a reproducible action on 
spond to more than one molecular species, the relative 
amount of the true active metabolite varying from one 
batch to the other. Thin-layer chromatography of com- 
pound X only shows one blue fluorescent spot. How- 
ever, it should be pointed out that the chromatographic 
behavior of a compound mainly depends on the num- 
ber of polar groups; thus, this procedure may fail to 
separate isomeric compounds having the same polarity 
whatever their fluorescence property. 
Attemps are in progress to obtain a better isolation 
of the active metabolite in collaboration with Jemmali 
and Lauriere. This step will permit identification of 
the active molecule. In this search, attention must be 
paid to some well-known derivatives that have to be 
seriously considered such as aflatoxin M, [ 16,171 and 
atlatoxin P[ 181 which correspond, respectively, to 
the hydroxylated and demcthylated forms of aflatoxil 
B,. Recent results by Pong and Wogan [ IS] have de- 
monstrated that both aflatoxin B1 and M, induce 
similar acute effects on RNA metabolism in viva in rat 
liver. However. the effect of MI on transcriptional 
activity in vitro has not yet been reported. 
Compound X appears to inhibit in vitro transcrip- 
tion by acting on RNA polymerase rather than on 
DNA template (figs. 2 and 3). This does not exclude 
the possibility of an b7 vitro effect of the active me- 
tabolite on DNA but indicates that its interaction 
with the protein-enzyme must also be considered to 
explain alterations in the catalytic properties of the 
RNA synthesizing system. 
It has been clearly demonstrated that many 
chemical carcinogens are not carcinogenic as such; 
they must be converted to reactive intermediates or 
ultimate forms which actually possess the carcinogenic 
potency [7,8]. In fact, it has been thought that only 
the ultimate forms bind to DNA in physiological con- 
ditions, that predicts a potential mutagenic property. 
It has been shown that aflatoxin B1 is capable of 
interacting with calf-thymus DNA in vitro [ZO] but 
there is no rigorous proof demonstrating that such a 
complex occurs in vivo. On the other hand, some 
mutagenic action of purified aflatoxin B, on trans- 
forming DNA has been reported by Mahler and 
Summers [ 2 I ] 
Aflatoxin B, is completely inactive on irz vitro 
transcription [4-61 and translation (manuscript in 
preparation) in mammalian systems, whereas com- 
pound X does inhibit their activity. It would be of in- 
terest to determine whether compound X resulting 
from enzymic conversion of aflatoxin B, might repre- 
sent the true reactive carcinogen. If so, a study of the 
interaction of compound X with macromolecules at 
the cellular level in the target cell may contribute to 
a better understanding of the mechanism of carcino- 
genesis induced by aflatoxin B1. 
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